Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains

被引：0
|
作者：
机构：
[1] [1,Hay, Duncan A.
[2] 2,Fedorov, Oleg
[3] 2,Martin, Sarah
[4] 2,Singleton, Dean C.
[5] 2,Tallant, Cynthia
[6] 2,Wells, Christopher
[7] Picaud, Sarah
[8] 2,Philpott, Martin
[9] 2,Monteiro, Octovia P.
[10] 2,Rogers, Catherine M.
[11] Conway, Stuart J.
[12] Rooney, Timothy P. C.
[13] 2,Tumber, Anthony
[14] 2,Yapp, Clarence
[15] Filippakopoulos, Panagis
[16] Bunnage, Mark E.
[17] 2,Müller, Susanne
[18] 2,Knapp, Stefan
[19] Schofield, Christopher J.
[20] 2,Brennan, Paul E.
来源：
Brennan, P.E. (paul.brennan@sgc.ox.ac.uk) | 1600年 / American Chemical Society卷 / 136期
关键词：
Small-molecule inhibitors that target bromodomains outside of the bromodomain and extra-terminal (BET) sub-family are lacking. Here; we describe highly potent and selective ligands for the bromodomain module of the human lysine acetyl transferase CBP/p300; developed from a series of 5-isoxazolyl-benzimidazoles. Our starting point was a fragment hit; which was optimized into a more potent and selective lead using parallel synthesis employing Suzuki couplings; benzimidazole-forming reactions; and reductive aminations. The selectivity of the lead compound against other bromodomain family members was investigated using a thermal stability assay; which revealed some inhibition of the structurally related BET family members. To address the BET selectivity issue; X-ray crystal structures of the lead compound bound to the CREB binding protein (CBP) and the first bromodomain of BRD4 (BRD4(1)) were used to guide the design of more selective compounds. The crystal structures obtained revealed two distinct binding modes. By varying the aryl substitution pattern and developing conformationally constrained analogues; selectivity for CBP over BRD4(1) was increased. The optimized compound is highly potent (K d = 21 nM) and selective; displaying 40-fold selectivity over BRD4(1). Cellular activity was demonstrated using fluorescence recovery after photo-bleaching (FRAP) and a p53 reporter assay. The optimized compounds are cell-active and have nanomolar affinity for CBP/p300; therefore; they should be useful in studies investigating the biological roles of CBP and p300 and to validate the CBP and p300 bromodomains as therapeutic targets. © 2014 American Chemical Society;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Journal article (JA)
引用
收藏
相关论文
共 50 条
  • [41] Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors
    Zhong, Xue
    Deng, Huiwen
    Long, Min
    Yin, Honglu
    Zhong, Qiu
    Zheng, Shilong
    Gong, Tao
    He, Ling
    Wang, Guangdi
    Sun, Qiu
    BIOORGANIC CHEMISTRY, 2023, 138
  • [42] Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins
    Thomas, Junius Eugene
    Wang, Mi
    Jiang, Wei
    Wang, Meilin
    Wang, Lu
    Wen, Bo
    Sun, Duxin
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (12) : 8178 - 8199
  • [43] Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma
    Chang, Qi
    Li, Jiayi
    Deng, Yue
    Zhou, Ruilin
    Wang, Bingwei
    Wang, Yujie
    Zhang, Mingming
    Huang, Xun
    Li, Yingxia
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (04) : 2466 - 2486
  • [44] Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers.
    Abbineni, Chandrasekhar
    Thiyagarajan, Saravanan
    Senaiar, Ramesh S.
    Mukherjee, Subhendu
    Jaleel, Mahaboobi
    Marappan, Sivapriya
    Raghavendra, N. R.
    Renukappa, Girish Aggunda
    Aravind, A. B.
    Kumar, Naveen R.
    Reddy, Venkata Siva
    Babu, Asha
    Srinivas, Akhila
    Yadlapalli, Prasad
    Gore, Suraj T.
    Hemasankar, Pathange
    Dey, Mamon
    Samiulla, D. S.
    Naik, Chandranath D.
    Antony, Thomas
    Nellore, Kavitha
    Chelur, Shekar
    Daginakatte, Girish
    Myllymaki, Mikko
    Wohlfahrt, Gerd
    Ramachandra, Murali
    Samajdar, Susanta
    CANCER RESEARCH, 2021, 81 (13)
  • [45] DISCOVERY OF THE P300 - A TRIBUTE
    BASHORE, TR
    VANDERMOLEN, MW
    BIOLOGICAL PSYCHOLOGY, 1991, 32 (2-3) : 155 - 171
  • [46] A Novel Approach to the Discovery of Small-Molecule Ligands of CDK2
    Martin, Mathew P.
    Alam, Riazul
    Betzi, Stephane
    Ingles, Donna J.
    Zhu, Jin-Yi
    Schoenbrunn, Ernst
    CHEMBIOCHEM, 2012, 13 (14) : 2128 - 2136
  • [47] Small-Molecule Inhibitors of Acetyltransferase p300 Identified by High-Throughput Screening Are Potent Anticancer Agents
    Yang, Heng
    Pinello, Christie E.
    Luo, Jian
    Li, Dawei
    Wang, Yunfei
    Zhao, Lisa Y.
    Jahn, Stephan C.
    Saldanha, Sanjay Adrian
    Planck, Jamie
    Geary, Kyla R.
    Ma, Haiching
    Law, Brian K.
    Roush, William R.
    Hodder, Peter
    Liao, Daiqing
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (05) : 610 - 620
  • [48] P300 IS A FUNCTIONAL HOMOLOG OF THE TRANSCRIPTIONAL COACTIVATOR CBP
    LUNDBLAD, JR
    KWOK, RPS
    LAURANCE, ME
    HARTER, ML
    GOODMAN, RH
    FASEB JOURNAL, 1995, 9 (06): : A1461 - A1461
  • [49] Chromatin recognition and regulation of the acetyltransferase CBP/p300
    Panne, D.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2014, 70 : C1586 - C1586
  • [50] Role of CBP/P300 in nuclear receptor signalling
    Chakravarti, D
    LaMorte, VJ
    Nelson, MC
    Nakajima, T
    Schulman, IG
    Juguilon, H
    Montminy, M
    Evans, RM
    NATURE, 1996, 383 (6595) : 99 - 103
12345